Website intended for a NZ health professional readership
This article, written by Rosemary Marks, provides information to help ensure the best health and wellbeing outcomes for your patients with Down syndrome and their whānau, by focusing on the care of children and young people. It highlights the most common issues you will need to consider, as well as those that can have serious consequences if missed
1. de Graaf G, Skladzien E, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in Australia and New Zealand. Genet Med 2022;24(12):2568–77.
2. Te Whatu Ora – Health New Zealand. Universal Newborn Hearing Screening and Early Intervention Programme: National Policy and Quality Standards: Diagnostic and amplification protocols. Wellington, NZ: Te Whatu Ora; 2023.
3. Clift AK, Coupland CAC, Keogh RH, et al. COVID-19 mortality risk in Down syndrome: Results from a cohort study of 8 million adults. Ann Intern Med 2021;174(4):572–76.
4. Mathan JJ, Gokul A, Simkin SK, et al. Topographic screening reveals keratoconus to be extremely common in Down syndrome. Clin Experiment Ophthalmol 2020;48:1160–67.
5. Ostermaier KK, Weaver AL, Myers SM, et al. Incidence of celiac disease in Down syndrome: A longitudinal, population-based birth cohort study. Clin Pediatr (Phila) 2020;59(12):1086–91.
6. Foley C, Killeen OG. Musculoskeletal anomalies in children with Down syndrome: an observational study. Arch Dis Child 2019;104(5):482–87.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
